EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseVergleichsstudieSystematische Übersicht

Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis

Han-Ying Tian, Chao Xu, Cheng-Jiang Liu, Yu-Zhen Li

International Archives of Allergy and Immunology · 2025

DOI: 10.1159/000548019 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Han-Ying Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The latest international joint guideline supports the use of second-generation H1 antihistamines (sgAHs) as the first-line treatment for chronic spontaneous urticaria (CSU).

Methods

PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for randomized controlled trials of various types of sgAHs in the treatment of CSU up to March 2025. For efficacy, the primary outcome was the change from baseline in the total symptom score, while the secondary outcomes were pruritus score and wheal score. For safety, the total numbers of all withdrawals due to adverse events and common adverse effects were extracted for each treatment, which included central nervous system side effects and anticholinergic side effects.

Results

We identified and included 24 randomized clinical trials (RCTs) involving 5,172 patients. Ebastine ranked first in the total symptom score (standardized mean difference [SMD)\ −2.80 [95% confidence interval (CI):−5.12 to −0.47]) and pruritus score (SMD −1.10 [95% CI: −2.06 to −0.13]), while olopatadine ranked first in the wheal score (SMD −0.84 [95% CI: −1.37 to −0.32]). Bepotastine besilate had a significantly lower incidence of somnolence in adverse events (odds ratio 0.15 [95% CI: 0.03–0.69]) than other sgAHs.

Conclusion

Both ebastine and olopatadine showed promising efficacy, and no significant differences were found in acceptability and safety compared with placebo. There are no meaningful differences in safety risks between different second-generation antihistamines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaHistamine H1 Antagonists, Non-SedatingHumansTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Adverse eventsChronic urticariaNetwork meta-analysisSecond-generation antihistaminesTotal symptom score

Substanzen

Histamine H1 Antagonists, Non-Sedating

Autor:innen und Institutionen

  • Harbin Medical University, Harbin, China.
  • Department of Dermatology, Second Clinical College of Harbin Medical University, Heilongjiang, China.
  • Department of Dermatology, Yinzhou District Second Hospital, Ningbo, China.
  • Department of General Medicine, Anhui Medical University, Hefei, China.
  • Department of Dermatology, Second Clinical College of Harbin Medical University, Heilongjiang, China, liyuzhen@hrbmu.edu.cn.

Zitieren

APA

Tian, H. Y., Xu, C., Liu, C. J., & Li, Y. Z. (2025). Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis. International Archives of Allergy and Immunology. https://doi.org/10.1159/000548019

Vancouver

Tian HY, Xu C, Liu CJ, Li YZ. Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis. International Archives of Allergy and Immunology. 2025. doi:10.1159/000548019

BibTeX
@article{Tian2025,
  author = {Tian, Han-Ying and Xu, Chao and Liu, Cheng-Jiang and Li, Yu-Zhen},
  title = {Comparative Effectiveness and Safety of Second-Generation Antihistamines Treatments for Chronic Urticaria: A Network Meta-Analysis},
  journal = {International Archives of Allergy and Immunology},
  year = {2025},
  doi = {10.1159/000548019}
}
Kostenlos starten →